Mike Moyer
Host, LifeSite Advisors
Replay available
PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call
PDS Biotechnology Corporation (NASDAQ: PDSB) Q1 2025 earnings conference call, held 2025-05-14. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Frank Badu-Addo
Chief Executive Officer
Dr. Kirk Shepherd
Chief Medical Officer
Lars Bosgaard
Chief Financial Officer
Mam Tani
Analyst, B. Riley Securities
Joe Panganese
Analyst, H.C. Wainwright
James Malloy
Analyst, Alliance Global Partners
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Pds Biotechnology Corporation.
Replay transcript excerpt
WEBVTT 00:00:00.655 -- 00:00:05.661 Greetings and welcome to the PDS Biotech first quarter and 2025 earnings 00:00:05.661 -- 00:00:10.968 conference call. At this time, all participants are in a listen-only mode. 00:00:10.968 -- 00:00:14.313 A brief question and answer session will follow the formal presentation. 00:00:14.313 -- 00:00:19.540 If anyone should require operator assistance during the conference, please press star 00:00:19.540 -- 00:00:25.127 zero on your telephone keypad. As a reminder, this conference is being recorded. 00:00:25.127 -- 00:00:30.136 It is now my pleasure to introduce your host, Mike Moyer, LifeSite Advisors. 00:00:30.136 -- 00:00:31.798 Thank you, sir. You may begin. 00:00:31.798 -- 00:00:33.798 Thank 00:00:34.040 -- 00:00:39.146 you, operator. Good morning, everyone, and welcome to PDS Biotech's first quarter 2025 00:00:39.146 -- 00:00:42.049 results and clinical programs update call. 00:00:42.049 -- 00:00:45.673 I am joined on the call today by the following members of the company's management team. 00:00:45.673 -- 00:00:48.777 Dr. Frank Badu-Addo, Chief Executive Officer, Dr. 00:00:48.777 -- 00:00:53.582 Kirk Shepherd, Chief Medical Officer, and Lars Bosgaard, Chief Financial Officer. 00:00:53.582 -- 00:00:57.867 Dr. Badu-Addo will begin with an overview of the company's recent progress in its clinical 00:00:57.867 -- 00:01:02.030 development program Mr. Bosgarb will review the financial results for the quarter ended 00:01:02.030 -- 00:01:04.334 March 31, 2025, 00:01:04.334 -- 00:01:09.521 and Dr. Shepherd will then join the call to help address questions from our 00:01:09.521 -- 00:01:14.348 covering analysts. As a reminder, during this call, we will be making forward-looking 00:01:14.348 -- 00:01:17.652 statements which are subject ...